Johnson & Johnson (JNJ) announced on Friday that it would be halting its Phase 2 field study on Mosnodenvir, previously known as JNJ-1802, which was investigating its effectiveness in preventing dengue virus in adults aged 18 to 65. This decision is part of a strategic shift in the company's research and development focus within its Communicable Diseases sector.
Earlier clinical trials, specifically phase 1 and phase 2a, indicated that Mosnodenvir was both safe and well-tolerated by participants. The company stated that comprehensive efficacy results from the Phase 2 field study will be made public following the completion of the ongoing final data analyses.
As of now, shares of Johnson & Johnson are trading at $159.24, marking a 0.78 percent decrease on the New York Stock Exchange.
